Compare AstraZeneca plc (AZN) vs Raytheon Technologies Corp (RTX) Price & Performance

AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.

The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.

RTX trades at $196.39, up 0.23% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten estimates, with Q1 2026 EPS of $1.78 surpassing the $1.51 expectation. Revenue grew to $88.6B in 2025, and net income margin improved to 8.03%. The company secured a $515 million Navy contract for SPY-6 radars, highlighting defense sector strength. Cash flow from operations reached $10.57B in 2025, supporting dividend payments and strategic investments.

The outlook for RTX is positive, driven by robust defense contracts, earnings growth, and a consensus price target of $213. Risks include reliance on government spending, competitive pressures, and macroeconomic volatility. Institutional sentiment remains bullish with 69% buy ratings, but investors should monitor debt levels and execution on production targets.